(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Senior physicians, cardiologists, urologists, psychologists, and pharmacologists critically review the relation between heart disease and erectile dysfunction (ED) and explain for the practicing physician the effective new treatment options available for the cardiac patient with ED. The authors detail in concise language the latest thinking about the risk of sexually induced cardiac events, the efficacy and risks to cardiac patients of drugs used to treat sexual dysfunction, and the expert guidelines developed by prominent organizations on the optimal approach to sexual dysfunction in the cardiac patient. They also discuss the physiology of ED and the currently available therapies (sildenafil, tadalafil, and vardenafil) may interact with the cardiac system, and the potential application of newer agents like phosphodiesterase-5 inhibitors to cardiovascular disease.
Contents:
Physiology of Erection and Causes of Erectile Dysfunction
Aristotelis G. Anastasiadis, Dmitry Droggin, Martin Burchardt, and Ridwan Shabsigh
Erectile Dysfunction: The Scope of the Problem
Culley C. Carson
Erectile Dysfunction and Cardiovascular Risk Factors
Robert A. Kloner
Psychologic Aspects of Erectile Dysfunction in Heart Patients
Raymond C. Rosen
Management of Erectile Dysfunction: An Overview
Harin Padma-Nathan
Sildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway
Ian H. Osterloh and Stephen C. Phillips
Phosphodiesterase-5 Inhibition: Importance to the Cardiovascular System
Jackie D. Corbin, Stephen R. Rannels, and Sharron H. Francis
The Hemodynamics of Phosphodiesterase-PDE5 Inhibitors
Graham Jackson
Cardiovascular Safety of Phosphodiesterase-5 Inhibitors
Robert A. Kloner
Effect of Phosphodiesterase-5 Inhibition on Coronary Blood Flow in Experimental Animals
YingJie Chen, Jay H. Traverse, and Robert J. Bache
Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease
Sameer Rohatgi and Howard C. Herrmann
Cardiovascular Effects of Nonphosphodiesterase-5 Inhibitor Erectile Dysfunction Therapies
Harin Padma-Nathan
Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition
Michael Sweeney and Richard L. Siegel
The Physiologic Cost of Sexual Activity
Robert F. DeBusk
Sexual Activity As a Trigger of Myocardial Infarction/Ischemia: Implications for Treating Erectile Dysfunction
Robert A. Kloner
Sex After Cardiac Events and Procedures: Counseling From the Cardiovascular Specialist's Perspective
Herman A. Taylor, Jr.
American College of Cardiology/American Heart Association Guidelines on the Use of Sildenafil in Patients With Cardiovascular Disease
Adolph M. Hutter, Jr.
Risk of Heart Attack After Sexual Activity: The Princeton Guidelines and Their Rationale
Robert F. DeBusk
Index
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: December, 2012
Pages: 300
Weight: 459g
Availability: Available
Subcategories: Cardiovascular Medicine
From the same series
